Ken Griffin Vericel Corp Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Vericel Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 34,800 shares of VCEL stock, worth $1.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,800

Previous 39,700 12.34%

Holding current value

$1.83 Million

Previous $1.82 Million 19.28%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$42.25 - $53.56 $2.9 Million - $3.68 Million	68,647 Added 686470.0%	68,657 $2.9 Million
Q2 2024 Aug 14, 2024	SELL	$41.71 - $52.9 $302,188 - $383,260	-7,245 Reduced 99.86%	10 $0
Q1 2024 May 15, 2024	SELL	$32.52 - $52.33 $376,126 - $605,248	-11,566 Reduced 61.45%	7,255 $377,000
Q4 2023 Feb 14, 2024	SELL	$30.85 - $37.09 $2.01 Million - $2.42 Million	-65,160 Reduced 77.59%	18,821 $670,000
Q3 2023 Nov 14, 2023	SELL	$31.69 - $39.25 $10.3 Million - $12.7 Million	-324,688 Reduced 79.45%	83,981 $2.82 Million
Q2 2023 Aug 14, 2023	BUY	$29.0 - $38.37 $11.8 Million - $15.6 Million	407,637 Added 39499.71%	408,669 $15.4 Million
Q1 2023 May 15, 2023	SELL	$23.85 - $31.34 $108,183 - $142,158	-4,536 Reduced 81.47%	1,032 $30,000
Q4 2022 Feb 14, 2023	SELL	$17.65 - $27.37 $1.54 Million - $2.38 Million	-87,056 Reduced 93.99%	5,568 $146,000
Q3 2022 Nov 14, 2022	SELL	$22.62 - $32.54 $3 Million - $4.31 Million	-132,578 Reduced 58.87%	92,624 $2.15 Million
Q2 2022 Aug 15, 2022	BUY	$22.88 - $39.45 $4.75 Million - $8.2 Million	207,792 Added 1193.52%	225,202 $5.67 Million
Q1 2022 May 16, 2022	BUY	$31.69 - $43.29 $34,351 - $46,926	1,084 Added 6.64%	17,410 $665,000
Q4 2021 Feb 14, 2022	SELL	$35.2 - $52.6 $3.17 Million - $4.74 Million	-90,138 Reduced 84.67%	16,326 $641,000
Q3 2021 Nov 15, 2021	BUY	$46.35 - $59.75 $2.68 Million - $3.45 Million	57,800 Added 118.77%	106,464 $5.2 Million
Q2 2021 Aug 16, 2021	SELL	$47.2 - $67.81 $450,429 - $647,110	-9,543 Reduced 16.39%	48,664 $2.55 Million
Q1 2021 May 17, 2021	SELL	$30.93 - $59.48 $276,266 - $531,275	-8,932 Reduced 13.3%	58,207 $3.23 Million
Q4 2020 Feb 16, 2021	SELL	$18.53 - $31.5 $2.12 Million - $3.6 Million	-114,201 Reduced 62.98%	67,139 $2.07 Million
Q3 2020 Nov 16, 2020	BUY	$14.68 - $19.12 $101,027 - $131,583	6,882 Added 3.94%	181,340 $3.36 Million
Q2 2020 Aug 14, 2020	BUY	$8.5 - $15.82 $473,696 - $881,632	55,729 Added 46.94%	174,458 $2.41 Million
Q1 2020 May 15, 2020	SELL	$7.25 - $19.22 $393,015 - $1.04 Million	-54,209 Reduced 31.35%	118,729 $1.09 Million
Q4 2019 Feb 14, 2020	BUY	$13.77 - $19.2 $2.13 Million - $2.98 Million	155,021 Added 865.22%	172,938 $3.01 Million
Q3 2019 Nov 14, 2019	SELL	$14.93 - $19.83 $719,073 - $955,072	-48,163 Reduced 72.89%	17,917 $271,000
Q2 2019 Aug 14, 2019	SELL	$15.01 - $18.89 $244,182 - $307,302	-16,268 Reduced 19.76%	66,080 $1.25 Million
Q1 2019 May 15, 2019	SELL	$16.23 - $20.29 $2.52 Million - $3.15 Million	-155,284 Reduced 65.35%	82,348 $0
Q4 2018 Feb 14, 2019	BUY	$10.77 - $18.44 $1.57 Million - $2.68 Million	145,566 Added 158.11%	237,632 $4.13 Million
Q3 2018 Nov 13, 2018	SELL	$9.1 - $14.8 $275,830 - $448,602	-30,311 Reduced 24.77%	92,066 $0
Q2 2018 Aug 10, 2018	BUY	$9.6 - $14.6 $611,731 - $930,341	63,722 Added 108.64%	122,377 $0
Q1 2018 May 11, 2018	BUY	$5.7 - $12.3 $243,429 - $525,296	42,707 Added 267.79%	58,655 $584,000
Q4 2017 Feb 09, 2018	SELL	$3.65 - $5.98 $84,716 - $138,795	-23,210 Reduced 59.27%	15,948 $87,000
Q3 2017 Nov 09, 2017	BUY	$3.0 - $6.0 $117,474 - $234,948	39,158	39,158 $235,000

Others Institutions Holding VCEL

# of Institutions

276

Shares Held

48.8M

Call Options Held

91.8K

Put Options Held

23.2K

View Full List

About Vericel Corp

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.48B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

More about VCEL

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account